Detail

Palivizumab

Description

Name: Palivizumab
Type: biotech
Groups: Array
Indication: For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
Accession Number: DB00110 ( BIOD00097, BTD00097)
Description: Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Synagispowder for solution50 mgintramuscular26-09-2002Canada
Synagispowder for solution100 mgintramuscular26-09-2002Canada
Synagisinjection, solution100 mg/mLintramuscular19-06-1998US
Synagisinjection, solution50 mg/.5mLintramuscular09-12-1999US
Synagissolution100 mgintramuscular01-01-1970Canada
Synagissolution50 mgintramuscular01-01-1970Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
SynagisPalivizumab
SynagisPalivizumab
SynagisPalivizumab
SynagisPalivizumab
SynagisPalivizumab
SynagisPalivizumab

Categories
  • Antiviral Agents

Pharmacology

Indication: For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
Pharmacodynamics: Not Available
Mechanism of action: Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: 18-20 days (in adults)
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
Dosage forms
FormRouteStrength
Injection, solutionintramuscular100 mg/mL
Injection, solutionintramuscular50 mg/.5mL
Powder for solutionintramuscular100 mg
Powder for solutionintramuscular50 mg
Solutionintramuscular100 mg
Solutionintramuscular50 mg

Prices
Unit descriptionCostUnit

Patents
CountryPatent NumberApprovedExpires (estimated)
2197684Canada2000-10-312015-08-09

Interactions

Drug Interactions
DrugInteraction
BelimumabThe risk or severity of adverse effects can be increased when Palivizumab is combined with Belimumab.

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Not Available

substituent:
  • Not Available

References

Synthesis Reference: Not Available
General Reference: Not Available
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic2/palivizumab.htm
Drugs.comhttp://www.drugs.com/cdi/palivizumab.html

ATC Codes:
  • Array

AHFS Codes:
  • 08:18.24

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?